Last updated: July 17, 2026

Application No. 18/561,506

EGFR TARGETING FC ANTIGEN BINDING FRAGMENT-DRUG CONJUGATES

Non-Final OA

Filed

Nov 16, 2023

Priority

May 25, 2021 — EU 21175808.1 +1 more

Examiner

CHASE, CAROL ANN

Art Unit

1646

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Merck Patent GmbH

OA Round

1 (Non-Final)

This examiner grants 45% of cases after interview

— +84.0% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 58 resolved cases, 2023–2026

Examiner Intelligence

CHASE, CAROL ANN View full profile →

Grants 45% of resolved cases

Career Allowance Rate

26 granted / 58 resolved

-15.2% vs TC avg

Strong +84% interview lift

Without

With

+84.0%

Interview Lift

resolved cases with interview

Typical timeline

3y 6m

Avg Prosecution

32 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

37.9%

-2.1% vs TC avg

§102

3.7%

-36.3% vs TC avg

§112

11.8%

-28.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 58 resolved cases

Prosecution Timeline

Nov 16, 2023

Application Filed

Apr 20, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/598,763

Patent 12577287

T CELL RECEPTORS AND METHODS OF USE THEREOF

4y 5m to grant Granted Mar 17, 2026

17/631,825

Patent 12570715

T CELL RECEPTORS AND METHODS OF USE THEREOF

4y 1m to grant Granted Mar 10, 2026

17/253,886

Patent 12559535

METHOD FOR THE IN VITRO DIFFERENTIATION AND MATURATION OF DENDRITIC CELLS FOR THERAPEUTIC USE

5y 2m to grant Granted Feb 24, 2026

17/999,496

Patent 12552851

T CELL RECEPTORS WITH VGLL1 SPECIFICITY AND USES THEREOF

3y 2m to grant Granted Feb 17, 2026

17/053,925

Patent 12527862

BACTERICIDAL/PERMEABILITY INCREASING PROTEIN FOR USE IN A METHOD OF IMMUNIZATION, PREFERABLY AS AN ADJUVANT IN A METHOD OF VACCINATION

5y 2m to grant Granted Jan 20, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

45%

Grant Probability

99%

With Interview (+84.0%)

3y 6m (~10m remaining)

Median Time to Grant

Low

PTA Risk

Based on 58 resolved cases by this examiner. Grant probability derived from career allowance rate.